CytomX Therapeutics Inc. (CTMX)
NASDAQ: CTMX
· Real-Time Price · USD
1.92
0.16 (9.09%)
At close: Aug 15, 2025, 3:47 PM
9.09% (1D)
| Bid | 1.85 |
| Market Cap | 315.81M |
| Revenue (ttm) | 147.56M |
| Net Income (ttm) | 41.6M |
| EPS (ttm) | 0.5 |
| PE Ratio (ttm) | 3.83 |
| Forward PE | -5.24 |
| Analyst | Buy |
| Ask | 1.96 |
| Volume | 8,754,895 |
| Avg. Volume (20D) | 2,755,741 |
| Open | 1.78 |
| Previous Close | 1.76 |
| Day's Range | 1.77 - 1.96 |
| 52-Week Range | 0.40 - 3.10 |
| Beta | 2.13 |
About CTMX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CTMX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CTMX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
CytomX Therapeutics Inc. is scheduled to release its earnings on
Nov 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+11.9%
CytomX Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
2 months ago
+4.93%
CytomX Therapeutics shares are trading higher after the company announced it dosed its first patient in the Phase 1 study of CX-801 plus KEYTRUDA.
